loader image
Saturday, December 20, 2025
70.5 F
McAllen
- Advertisement -

New Study Reveals Anti-Cancer Properties In Kencur Ginger

Translate to Spanish or other 102 languages!

While previous studies on EMC indicated its anti-cancer potential by decreasing the expression of mitochondrial transcription factor A (TFAM), which is associated with cancer cell proliferation, the exact mechanism remained unclear until now. Image source Ginger: Facebook for illustration purposes
While previous studies on EMC indicated its anti-cancer potential by decreasing the expression of mitochondrial transcription factor A (TFAM), which is associated with cancer cell proliferation, the exact mechanism remained unclear until now. Image source Ginger: Facebook for illustration purposes

Mega Doctor News

- Advertisement -

BOsaka Metropolitan University

You may know it as an aromatic spice to add flavor to your dishes or as a soothing herbal remedy to use for upset stomachs, but researchers from Osaka Metropolitan University have uncovered promising findings that Kencur, a tropical plant in the ginger family native to Southeast Asia, possesses anti-cancer effects.

Led by Associate Professor Akiko Kojima of the Graduate School of Human Life and Ecology, the researchers demonstrated that Kencur extract and its main active component, ethyl p-methoxycinnamate (EMC), significantly suppressed cancer cell growth at the cellular and animal levels.

- Advertisement -

While previous studies on EMC indicated its anti-cancer potential by decreasing the expression of mitochondrial transcription factor A (TFAM), which is associated with cancer cell proliferation, the exact mechanism remained unclear until now.

“The results of this study confirm the anti-cancer effects of Kencur extract and its main active ingredient, EMC. It is highly expected that TFAM will become a new marker for anti-cancer effects in the future as research advances in related fields,” Professor Kojima stated.

Their findings were published in Heliyon.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

FDA Approves Daily Pill to Treat Low Libido in Women After Menopause

On December 15, 2025, the U.S. Food and Drug Administration (FDA) approved the medication Addyi (flibanserin) for the treatment of hypoactive sexual desire disorder (HSDD) in postmenopausal women under the age of 65.

Heart Association Highlights 2025’s Major Research Findings

In 2025, cardiovascular investigators worldwide reported findings that could help fill important gaps in preventing and managing conditions including high blood pressure, stroke, heart failure, dangerous blood clots and aortic stenosis.

Uniting Experts to Revolutionize Cancer Treatment

More than 70% of all cancers are impacted by mutations caused by a group of DNA-editing enzymes that drives tumor growth and drug resistance. The apolipoprotein B mRNA-editing enzyme catalytic polypeptide, or APOBEC, family, is a dominant factor in many cancers including bladder, breast, cervical, head and neck and lung.

Early Findings Show Breast Cancer Vaccine Produces Immune Response

Cleveland Clinic released its findings from the first phase of the clinical trial for the preventive breast cancer vaccine. 
- Advertisement -
×